BI
BIXT.US Bioxytran Inc
- Market cap
- USD 2.52M
- P/E
- -
- P/B
- 77.85x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BIXT.US undervalued?
Graham numberThe Graham number of Bioxytran Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bioxytran Inc fundamental analysis
No fundamental analysis for Bioxytran Inc yet.
Bioxytran Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bioxytran Inc
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address viral infections, glycovirology, and oxygen delivery, hypoxia and degenerative diseases in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and …
Full company profileBioxytran Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bioxytran Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 246K | 191K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 150K | 87.1K | 0.00 | - | - | - | - | - | - | - | - |
| Operating Income | -671K | -311K | -215K | -1.63M | -1.27M | -4.21M | -2.44M | -3.81M | -2.23M | -1.85M | -5.19M |
| EBITDA | - | -293K | -288K | - | - | - | -2.14M | -4.01M | -1.60M | -1.93M | -5.11M |
| Net Income | -697K | -318K | -296K | -1.86M | -2.48M | -4.03M | -2.47M | -4.47M | -2.37M | -2.12M | -5.38M |
| EPS | - | -0.09 | 0.00 | -0.02 | -0.03 | -0.04 | -0.02 | -0.03 | -0.03 | -0.02 | -0.05 |
| Balance Sheet | |||||||||||
| Total Assets | 51.7K | 726K | 36.4K | 220K | 326K | 119K | 371K | 139K | 139K | 659K | 333K |
| Total Liabilities | 342K | 183K | 262K | 1.02M | 2.27M | 3.28M | 3.67M | 3.24M | 1.93M | 3.25M | 5.27M |
| Shareholders' Equity | -291K | 542K | -225K | -799K | -1.94M | -3.16M | -2.71M | -2.42M | -1.79M | -2.59M | -4.94M |
| Cash & Short-term Investments | 11.1K | 15.3K | 36.4K | 170K | 41.7K | 72.4K | 295K | 26.1K | 5.15K | 510K | 177K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -42.4K | 440.00 | -186K | -431K | -1.10M | -1.70M | -1.80M | -775K | -55.7K | -526K | -1.18M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 10.0K | 36.9K | 32.2K | 44.3K | 28.2K | 23.1K | 37.2K |
| Free Cash Flow | - | -18.5K | -186K | -431K | -1.11M | -1.73M | -1.84M | -820K | -83.9K | -550K | -1.21M |
| Ratios | |||||||||||
| ROE | - | -58.7% | - | - | - | - | - | - | - | - | - |
| ROA | -1,348.4% | -43.9% | -814.1% | -846.2% | -760.0% | -3,379.8% | -666.7% | -3,208.8% | -1,706.4% | -322.4% | -1,613.1% |
| Net Profit Margin | -282.7% | -166.6% | - | - | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Bioxytran Inc dividends
Bioxytran Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:30 on Aug 22, 2018.
Who owns Bioxytran Inc
- Insiders 0.62%
- Institutions 0.00%
- Public & others 99.38%
- Shares outstanding 115M
- Free float 114M
Bioxytran Inc company profile
- Company name
- Bioxytran Inc
- Ticker
- BIXT.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- December
- Address
- 75 2nd Avenue, Needham, MA, United States, 02494
- Phone
- 617 454 1199
- Website
- bioxytraninc.com
About Bioxytran Inc
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address viral infections, glycovirology, and oxygen delivery, hypoxia and degenerative diseases in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-3, a type of galectin for treatment of mild to moderate cases of Covid-19. Bioxytran, Inc. has collaboration with University of Minnesota for advance novel carbohydrate-based therapeutics. The company was founded in 2008 and is headquartered in Needham, Massachusetts.
Bioxytran Inc management
2- Dr. David Platt Ph.D.Chairman, CEO, President & Secretary · born 1953
- Mr. Ola Soderquist C.M.A., C.P.A., CM&AA, M.B.A.CFO & Treasurer · born 1962